Dorsey Wright & Associates Makes New $1.64 Million Investment in Boston Scientific Corporation $BSX

Dorsey Wright & Associates purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 15,232 shares of the medical equipment provider’s stock, valued at approximately $1,636,000.

Several other large investors have also recently made changes to their positions in the stock. TD Waterhouse Canada Inc. lifted its stake in Boston Scientific by 106.1% during the second quarter. TD Waterhouse Canada Inc. now owns 120,805 shares of the medical equipment provider’s stock worth $12,651,000 after purchasing an additional 62,204 shares in the last quarter. Aspen Investment Management Inc raised its holdings in shares of Boston Scientific by 20.4% in the 2nd quarter. Aspen Investment Management Inc now owns 10,474 shares of the medical equipment provider’s stock valued at $1,125,000 after buying an additional 1,774 shares during the period. Traub Capital Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $43,000. Wealthspire Advisors LLC boosted its holdings in Boston Scientific by 11.6% during the 2nd quarter. Wealthspire Advisors LLC now owns 6,926 shares of the medical equipment provider’s stock valued at $744,000 after acquiring an additional 719 shares during the period. Finally, Vanguard Group Inc. grew its position in Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of BSX opened at $99.23 on Wednesday. The firm has a market capitalization of $147.10 billion, a price-to-earnings ratio of 53.06, a PEG ratio of 2.02 and a beta of 0.58. The firm’s fifty day simple moving average is $99.41 and its 200-day simple moving average is $102.51. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the company posted $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on BSX shares. BTIG Research reissued a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Wells Fargo & Company raised their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Boston Scientific in a research note on Monday, September 29th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $123.77.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 175,782 shares of company stock worth $17,742,314. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.